Carmustine
- TRADE NAMES: Becenun; BiCNU (Bristol-Myers Squibb); Carmubris; Gliadel Wafer (Guilford); Nitrumon
- INDICATIONS: Brain tumors, Hodgkin’s disease, multiple myeloma
- CLASS: Alkylating agent, Nitrosourea
- HALF-LIFE: initial: 1.4 minutes; secondary: 20 minutes
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Aldesleukin, Cimetidine, Clorazepate
PREGNANCY CATEGORY: D
Please login to see the rest of this drug profile
SKIN.
HAIR.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
HEMATOLOGIC.
LOCAL.
NEUROMUSCULAR/SKELETAL.
OCULAR.
RENAL.
RESPIRATORY.
OTHER.
Page last updated 07/31/2023
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric